SRR934937
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.737
- G2M_CHECKPOINT+0.709
- MYC_TARGETS_V1+0.631
- MYC_TARGETS_V2+0.521
- MITOTIC_SPINDLE+0.442
- DNA_REPAIR+0.414
- TGF_BETA_SIGNALING+0.313
- WNT_BETA_CATENIN_SIGNALING+0.310
- UNFOLDED_PROTEIN_RESPONSE+0.266
- MTORC1_SIGNALING+0.257
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.412
- KRAS_SIGNALING_DN-0.411
- MYOGENESIS-0.391
- XENOBIOTIC_METABOLISM-0.371
- BILE_ACID_METABOLISM-0.359
- INFLAMMATORY_RESPONSE-0.346
- ESTROGEN_RESPONSE_EARLY-0.342
- INTERFERON_GAMMA_RESPONSE-0.334
- ESTROGEN_RESPONSE_LATE-0.273
- COMPLEMENT-0.264
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934990 | — | — | 0.946 |
| 2 | SRR934744 | — | — | 0.944 |
| 3 | 4938761D-0762-4984-A399-BC036D6D2140 | — | — | 0.939 |
| 4 | D902E43A-F384-432A-B690-D20BFCC78443 | — | — | 0.936 |
| 5 | 2B4FA61A-C1A7-49BD-9438-2865D386EAF2 | — | — | 0.930 |
| 6 | SRR934879 | — | — | 0.925 |
| 7 | SRR934880 | — | — | 0.922 |
| 8 | C6A16A8F-0AB7-42E9-A068-15EECF2912D3 | — | — | 0.922 |
| 9 | CA366342-0949-4941-8AE6-984BAF032886 | — | — | 0.917 |
| 10 | ERR2598226 | fetal | fetal | 0.915 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.737 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.709 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.631 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.521 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.442 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.414 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.313 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.266 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.257 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.176 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.130 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.115 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.075 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.062 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.005 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.005 | Idelalisib | — uncovered |